XEN-1101 is under clinical development by Xenon Pharmaceuticals and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase II drugs for Major Depressive Disorder have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XEN-1101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XEN-1101 overview
XEN-1101 (1OP-2198) is under development for the treatment of partial seizure (focal-onset seizures), tonic-clonic (grand mal) seizure and major depressive disorder. The drug candidate is a small molecule administered orally as powder-in-capsule formulation. It acts by targeting potassium voltage-gated channel subfamily KQT Member 2 and 3 (KCNQ2/3). It was also under development for the treatment of neuro-ophthalmology disorders.
Xenon Pharmaceuticals overview
Xenon Pharmaceuticals (Xenon) is a clinical-stage biopharmaceutical company that develops innovative therapeutics for neurological disorders. The company’s pipeline products include XEN1101, NBI-921352, and XEN496. XEN1101 is a differentiated Kv7 potassium channel opener under development to treat focal onset seizures, major depressive disorder and primary generalized tonic-clonic seizures. NBI-921352 and XEN496 are under development for treating focal-onset seizures in adults, pediatric epilepsy and orphan pediatric epilepsy. The company collaborates with other pharmaceutical companies for the development of therapeutic drug candidates. It operates in Canada and the US. Xenon is headquartered in Burnaby, British Columbia, Canada.
For a complete picture of XEN-1101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
